Risk of Cognitive Impairment in Patients With Parkinson’s Disease With Visual Hallucinations and Subjective Cognitive Complaints
- Author:
Diego SANTOS-GARCÍA
1
;
Teresa de Deus FONTICOBA
;
Carlos Cores BARTOLOMÉ
;
Maria J. Feal PAINCEIRAS
;
Jose M. Paz GONZÁLEZ
;
Cristina Martínez MIRÓ
;
Silvia JESÚS
;
Miquel AGUILAR
;
Pau PASTOR
;
Lluís PLANELLAS
;
Marina COSGAYA
;
Juan García CALDENTEY
;
Nuria CABALLOL
;
Ines LEGARDA
;
Jorge Hernández VARA
;
Iria CABO
;
Lydia López MANZANARES
;
Isabel González ARAMBURU
;
Maria A. Ávila RIVERA
;
Víctor Gómez MAYORDOMO
;
Víctor NOGUEIRA
;
Víctor PUENTE
;
Julio Dotor GARCÍA-SOTO
;
Carmen BORRUÉ
;
Berta Solano VILA
;
María Álvarez SAUCO
;
Lydia VELA
;
Sonia ESCALANTE
;
Esther CUBO
;
Francisco Carrillo PADILLA
;
Juan C. Martínez CASTRILLO
;
Pilar Sánchez ALONSO
;
Maria G. Alonso LOSADA
;
Nuria López ARIZTEGUI
;
Itziar GASTÓN
;
Jaime KULISEVSKY
;
Marta Blázquez ESTRADA
;
Manuel SEIJO
;
Javier Rúiz MARTÍNEZ
;
Caridad VALERO
;
Mónica KURTIS
;
Oriol de FÁBREGUES
;
Jessica González ARDURA
;
Ruben Alonso REDONDO
;
Carlos ORDÁS
;
Luis M. López DÍAZ L
;
Darrian MCAFEE
;
Pablo MARTINEZ-MARTIN
;
Pablo MIR
;
Author Information
- Publication Type:ORIGINAL ARTICLE
- From:Journal of Clinical Neurology 2023;19(4):344-357
- CountryRepublic of Korea
- Language:English
-
Abstract:
Background:and Purpose Visual hallucinations (VH) and subjective cognitive complaints (SCC) are associated with cognitive impairment (CI) in Parkinson’s disease. Our aims were to determine the association between VH and SCC and the risk of CI development in a cohort of patients with Parkinson’s disease and normal cognition (PD-NC).
Methods:Patients with PD-NC (total score of >80 on the Parkinson’s Disease Cognitive Rating Scale [PD-CRS]) recruited from the Spanish COPPADIS cohort from January 2016 to November 2017 were followed up after 2 years. Subjects with a score of ≥1 on domain 5 and item 13 of the Non-Motor Symptoms Scale at baseline (V0) were considered as “with SCC” and “with VH,” respectively. CI at the 2-year follow-up (plus or minus 1 month) (V2) was defined as a PD-CRS total score of <81.
Results:At V0 (n=376, 58.2% males, age 61.14±8.73 years [mean±SD]), the frequencies of VH and SCC were 13.6% and 62.2%, respectively. VH were more frequent in patients with SCC than in those without: 18.8% (44/234) vs 4.9% (7/142), p<0.0001. At V2, 15.2% (57/376) of the patients had developed CI. VH presenting at V0 was associated with a higher risk of CI at V2 (odds ratio [OR]=2.68, 95% confidence interval=1.05–6.83, p=0.039) after controlling for the effects of age, disease duration, education, medication, motor and nonmotor status, mood, and PD-CRS total score at V0. Although SCC were not associated with CI at V2, presenting both VH and SCC at V0 increased the probability of having CI at V2 (OR=3.71, 95% confidence interval=1.36–10.17, p=0.011).
Conclusions:VH were associated with the development of SCC and CI at the 2-year follow-up in patients with PD-NC.
